Learning
Objectives
After completion of this activity, the participant should be better able to:
Assess patients’ level of risk for CINV based on their personal risk factors and emetogenicity of their chemotherapy regimen
Recognize the potential differences among agents and their usage for acute and delayed CINV
Implement guidelines into practice for the prevention and treatment of CINV
Discuss ongoing studies, approaches under research, and new agents for CINV
Dinner Meeting and Studio Videotaping Sunday,
May 31, 2009 6:00 PM – 7:30 PM
Rosen Plaza Hotel,
Ballroom B
9700 International Drive
Orlando, Florida
To be held during the
2009 ASCO Annual Meeting* Registration and Dinner: 6:00 PM – 6:30 PM Program and Videotaping: 6:30 PM – 7:30 PM
Be a Part of the Videotaped Question-and-Answer Session to Be Broadcast on MedscapeCMESM
Faculty
Lee S. Schwartzberg,
MD,
Moderator Clinical Professor
University of Tennessee
School of Medicine
Medical Director
The West Clinic
Memphis, Tennessee
Paul J. Hesketh, MD
Professor of Medicine
Tufts University School of Medicine
Chief, Division of Hematology/Oncology
St. Elizabeth’s Medical Center
Boston, Massachusetts
Mark G. Kris, MD
Professor of Medicine
Weill Cornell Medical College
Chief, Thoracic Oncology Service
Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York
All faculty and planners participating in continuing medical education activities sponsored by New York Medical College are expected to disclose to the audience any significant support or substantial relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis. Complete disclosures will be provided at the time of the activity.
Program
Overview
Despite the availability of effective antiemetics, chemotherapy-induced nausea and vomiting (CINV) remains a significant problem for oncology patients.
In the community setting, three fourths of patients reported nausea on days 2-5 after starting cisplatin-, carboplatin-, or doxorubicin-containing regimens.
In a 2007 study, patients with breast cancer reported experiencing nausea or vomiting 37% and 13%, respectively, at 24 hours; and 70% and 15%, respectively, during days 2-5.
Indeed, nausea and vomiting are the number one adverse event patients fear.
Suboptimal treatment of emesis impairs quality of life, increases healthcare resources, and can impair adherence to treatment.
To adequately prevent and treat CINV, oncologists must:
Assess patient risk factors for nausea and vomiting
Assess the emetogenic potential of a particular regimen, which is the most predictive risk factor for CINV
Recognize the increased emetogenicity of certain chemotherapy combinations
Accurately estimate the CINV potential with oral agents
Agenda CHEMOTHERAPY-INDUCED NAUSEA
AND VOMITING: An Overview of a Persistent Problem Lee S. Schwartzberg, MD, Moderator
PATIENT PROFILE 1 A Patient With Breast Cancer Receiving Anthracycline and Cyclophosphamide (AC) Mark G. Kris, MD
Clinical Challenges
Evidence-Based Prevention and Treatment of Acute CINV
Panel Discussion
PATIENT PROFILE 2 A Patient With Lung Cancer Receiving Cisplatin-Containing Chemotherapy Paul J. Hesketh, MD
Clinical Challenges
Evidence-Based Prevention and Treatment of Delayed CINV
Panel Discussion
Question-and-Answer Session Closing Remarks
Sponsored by: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of New York Medical College (NYMC) and Continuing Education Alliance. NYMC is accredited by the ACCME to provide continuing medical education for physicians. NYMC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Developed by: This educational activity is supported by an educational grant from Eisai Inc.
*Not an official event of the ASCO meeting. Not sponsored or endorsed by ASCO or The ASCO Cancer Foundation.
